Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization

Table 1 Multiple logistic regression of aggressiveness index (score = 4/score > 4) on liver function parameter

All models in total cohort	OR	se(OR)	P value	95%CI
Variables included together in the model
Total Bilirubin (mg/dL)	2.044	0.875	0.095	0.883 to 4.729
ALKP (IU/mL)	1.013	0.006	0.046	1.000 to 1.025
GGTP (IU/mL)	0.995	0.002	0.045	0.990 to 0.999
AST (IU/L)	1.002	0.003	0.442	0.996 to 1.009
Albumin (g/dL)	3.197	1.74	0.033	0.101 to 9.288
Platelets (× 109/L)	1.014	0.008	0.056	1.000 to 1.029
WBC (× 109/L)	0.811	0.121	0.158	0.606 to 1.085
Lymphocyte (× 109/L)	1.311	0.354	0.315	0.773 to 2.227
Final model from stepwise method in backward
ALKP (IU/mL)	1.014	0.006	0.017	1.003 to 1.026
GGTP (IU/mL)	0.996	0.002	0.053	0.991 to 1.000
Albumin (g/dL)	2.562	1.082	0.026	1.120 to 5.863

Aggressiveness index (sum of scores): MTD (in tertiles): MTD < 4.5; 4.5 ≤ MTD ≤ 9.6; MTD > 9.6; scores 1, 2, 3 respectively; AFP (cut-off): AFP < 100; 100 ≤ AFP ≤ 1000; AFP > 1000; scores 1, 2, 3 respectively; PVT (no/yes): PVT (no); PVT (yes); scores 1, 3 respectively; nodules (number): Nodules ≤ 3; nodules > 3; scores 1, 3 respectively. AFP: Alpha-fetoprotein; MTD: Maximum tumor diameter; PVT: Portal vein thrombosis; ALKP: Alkaline phosphatase; GGTP: Gamma glutamyl transpeptidae; AST: Aspartate aminotransaminase; Hb: Haemoglobin; Plt: Platelet count; WBC: White blood cell.